These findings imply that Mettl3 deletion in MSCs accelerates AML progression, regardless of whether it is induced before or after AML cell transplantation, and that METTL3 in MSCs may serve as a repressor of AML development. Here, METTL3 is linked to acute myeloid leukemia.